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Abstract 
Background 
Clinical practice guidelines are statements of recommendations for patient care. Studies 
have shown that guideline recommendations do not always depend on evidence from 
clinical trials or systematic reviews. It is unknown whether no high quality evidence 
exists, evidence exists but authors were unaware of it, or advanced statistical methods 
were not available to them to address their questions. Our objective was to compare the 
guideline recommendations for first-line medical therapy for primary open-angle 
glaucoma (POAG) from each major update of the American Academy of 
Ophthalmology’s (AAO) Preferred Practice Patterns (PPPs) with the actual evidence base 
available at the time.  
 Methods 
We identified and extracted recommendations relevant to first-line medical therapy for 
POAG from each version of the AAO PPP. We searched MEDLINE, EMBASE, and 
CENTRAL for randomized controlled trials published up to March 2014. We analyzed 
intraocular pressure (IOP) outcome data as available at the time of each major guideline 
update. We used network meta-analysis to determine which of all drugs “works best.” 
Results 
We identified 9 versions of AAO’s guideline for POAG published between 1989 and 
2010. Based on similarity in treatment recommendations or discussion, we grouped these 
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guidelines into 5 sets: 1989-1992, 1996, 2000-2003; 2005-2006, and 2010. The 2010 
guideline recommended prostaglandins as initial treatment, but previous sets presented 
treatment options without recommending one drug (or class) over another. Based on a 
series of network meta-analyses of trials published up to around the time of the latest 
guideline in each set, all drugs are more effective than placebo or no treatment at each 
time point, but effect size appears to decrease over time. Network meta-analysis indicated 
that the most effective drug and class (at time point analyzed) were: levobunolol and beta 
blockers (1991), levobunolol and alpha agonists (1995), travoprost and prostaglandins 
(2002), bimatoprost and prostaglandins (2004 and 2009). 
Conclusions 
Network meta-analysis improves our understanding of the comparative effectiveness of 
multiple interventions. Had network meta-analysis been available, the AAO POAG PPP 
could have recommended prostaglandins (current first-line treatment) seven years before 
it actually did. Guideline developers should consider using results from network meta-
analyses in forming future recommendations.  
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1 Introduction  
 Clinical practice guidelines are statements of recommendations for patient care 
that are intended to be based on the best available evidence.
1, 2
 Historically, guidelines 
had primarily represented the opinions of individual authors or the consensus of experts.
3
 
With the advent of evidence-based medicine, however, guidelines have increasingly 
made use of randomized controlled trials (RCTs) and synthesis of RCTs in the form of 
systematic reviews and meta-analyses to form the basis of recommendations.
2
 Despite the 
push towards evidence-based guidelines, there may still be many recommendations that 
are based on lower levels of evidence. Tricoci et al., for example, examined 17 recent 
cardiovascular guidelines and found that among the 16 guidelines that reported levels of 
evidence, recommendations were most frequently based on expert opinion, case studies, 
or standard of care.
4
 It is unknown in these cases whether no high quality evidence exists, 
evidence exists but authors were unaware of it, or advanced statistical methods were not 
available for them to address their questions. 
 When quantitatively evaluating the evidence base to make a guideline 
recommendation, the standard meta-analytic techniques may not always be adequate. A 
standard meta-analysis can only compare two treatments at a time, and only those 
treatments that have been compared directly in clinical trials. When developing a 
guideline for a particular condition, in many cases multiple treatment options must be 
considered, and direct comparisons may be available only for some pairs of treatments. In 
these cases, an alternative to the standard meta-analysis may be used, the network meta-
analysis. A network meta-analysis looks across the entire network of trials of treatments 
for a specific condition and uses information from both direct and indirect comparisons 
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(i.e. using studies comparing treatments A and B and studies comparing B and C to 
estimate the comparison between A and C) to make inferences about the comparative 
effectiveness of all treatments in a single analysis.
5,6
 Since they enable an “all-way” 
comparison, network meta-analyses are particularly suited for informing evidence-based 
guideline recommendations. 
 Clinical fields which could most benefit from network meta-analysis are those for 
which a number of treatment options are available. One such area is primary open-angle 
glaucoma (POAG). POAG is an eye condition in which damage has occurred to the optic 
nerve and is associated with factors such as high intraocular pressure (IOP), age, and 
being African American.
7
 POAG makes up the majority of glaucoma cases.
8
 Since IOP is 
the only known modifiable risk factor for POAG, treatment efficacy is generally 
determined by reduction in IOP.
7,9
 One of the earliest sets of guidelines that has been 
influential in the care of POAG is the American Academy of Ophthalmology’s (AAO) 
POAG Preferred Practice Pattern (PPP).
7, 10-17
 The first version of this guideline was 
published in 1989, with major revisions being published approximately every three to 
five years. 
When the AAO PPP guideline was first developed, evidence was gathered based 
on the guideline panel members’ preexisting knowledge; each member submitted what 
they considered seminal works and these works were distributed among the rest of the 
panel.
18
 In 1996, the panel began using literature searching methods to gather evidence, 
though details of the search were not reported. The panel also began rating the strength of 
the evidence in three levels: “I” for evidence from RCTs, “II” for “an appropriately 
controlled case series and sufficient statistical analysis,” and “III” for “expert opinion.”
12
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In the 2000 publication, the panel started reporting more details about the literature 
search, such as databases searched and publication years included.
13
 The criteria for 
strength of the evidence was also revised. “I” represented “strong evidence in support of 
the statement” based on study design, study populations, general quality, and statistical 
methods.
13
 “II” represented “substantial evidence in support of the statement” based on 
lacking one or more of the components for level “I” categorization. The definition for 
“III,” similar to before, represented a “consensus of expert opinion.”
13
 In 2010, the 
categorizations for strength of evidence were again redefined.
17
 “I” was for evidence 
based on high quality RCTs or meta-analyses. “II” represented evidence from well-
designed non-randomized controlled trials, cohort studies, case-control studies, or 
multiple-time series studies. Support was rated as “III” for evidence from descriptive 
studies, case reports, or expert committee/organization reports.
17
 
By using a cumulative network meta-analysis (i.e. conducting network meta-
analysis on a collection of studies published up to a time point), the evidence base for 
first line medical treatments can be compared with the recommendations for treatment for 
each major revision in the AAO guideline. Findings from this study will inform guideline 
developers about the potential benefits of incorporating the results of network meta-
analyses to form recommendations in the future. This study is not intended as criticism of 
guideline developers for not using statistical methods that were undeveloped at the time. 
Rather, we would like to examine what impact such techniques would have had, had they 
been available at the time. 
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2 Objective 
 The objective of this study was to compare the clinical recommendations for first-
line medical therapy for POAG from each major update of AAO’s POAG PPP with the 
actual evidence base as determined by network meta-analysis available at the time of 
each major update.  
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3 Methods 
3.1 Guideline identification and extraction 
 We identified nine versions of the AAO’s POAG PPP from the AAO website 
(http://www.aao.org/preferred-practice-patterns-publication) from 1989 to 2010, updated 
about every three to five years. Since only the latest version could be obtained online, we 
contacted the AAO’s librarian who provided the remaining versions.
19
 One individual 
reviewed each version of the guideline, identified sections discussing treatment for 
POAG, and extracted recommendations on specific drugs or drug classes for initial 
treatment, references cited for recommendations, and numerical estimates of efficacy or 
effectiveness (i.e. reduction of IOP) for drugs or drug classes. If a guideline included no 
specific recommendation for a drug or drug class, we extracted general recommendations 
for POAG management with medical therapies (e.g. “Medical therapy should be initial 
treatment for POAG”), as well as discussions about available medical therapies (e.g. 
“Treatment A is most frequently prescribed as initial treatment”). We considered 
recommendations evidence-based if they were based on a least one high-quality large 
RCT or a systematic review. When consecutive guideline versions presented identical 
recommendations or discussions regarding medical treatment, we grouped them together. 
Therefore, the nine guidelines were divided into five groups based on their 
recommendations. 
3.2 Systematic review and network meta-analysis 
This study was conducted using RCTs identified from an ongoing systematic 
review.
20
 We performed a network meta-analysis for each group of guidelines. Based on 
the latest guideline in each group, each corresponding network meta-analysis was 
comprised of all eligible studies published either up to the stopping point for the literature 
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search reported in the guideline or, if such a point is not reported, a year before that 
guideline was published (to allow for lag time between publication and inclusion of 
evidence in guideline). An additional analysis was performed with all studies obtained 
from the published literature up to 2014. 
3.2.1 Eligibility criteria 
 The eligibility criteria described here are the same as the underlying systematic 
review, unless otherwise noted.
20
 Eligible studies were RCTs with at least 60% of 
participants having a diagnosis of POAG or ocular hypertension (OHT), as defined by the 
trial. Trials included in this analysis also had to evaluate first line medical treatments for 
POAG or OHT, and compared single active treatments with no treatment, placebo, or 
other single active treatments. 
Trials were excluded if less than 10 participants were enrolled per treatment arm 
or if participants were followed for outcomes less than 28 days after randomization. 
 For this analysis, we examined mean IOP at 3 months as a continuous variable in 
units of mmHg as the primary outcome. When a trial measured IOP multiple ways, the 
priority for selection of IOP measurement was based on the following order: mean 
diurnal IOP, 24-hour mean IOP, peak IOP, morning IOP, and trough IOP. If a trial did 
not report IOP values at 3 months, we used data from the closest follow-up time point 
instead. IOP was selected as the primary outcome based on a preliminary analysis of 
guidelines indicating that it is the primary efficacy endpoint on which guideline 
recommendations were made.
7
 
3.2.2 Identification of included studies 
 We searched the Cochrane Register of Controlled Trials (CENTRAL) in The 
Cochrane Library, MEDLINE, and EMBASE in November 17, 2009 and the search was 
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updated in March 11, 2014. Although the Food and Drug Administration (FDA) was 
searched for additional trials for the underlying systematic review, we did not include 
these trials in this project because none of the guidelines reported searching the FDA 
website. The search strategies are available in Appendix 1. Two individuals 
independently screened titles and abstracts of identified records for potential eligibility. 
We obtained the full texts for records considered potentially eligible and these articles 
were then assessed independently for eligibility for the review by two individuals. When 
feasible, two individuals assessed the non-English language reports for eligibility, 
otherwise a single individual who was a native or fluent speaker of the language was 
responsible for assessing eligibility. We resolved discrepancies in classification of 
eligibility of full text articles through discussion or consultation with a third person. 
3.2.3 Data abstraction and management 
Two individuals independently abstracted data from eligible trials on the study 
design, participant and intervention characteristics, outcomes, risk of bias, and 
quantitative results on treatment effects and safety using electronic forms developed and 
maintained in the Systematic Review Data Repository (http://srdr.ahrq.gov/).
21,22
 We 
used the Cochrane Risk of Bias Tool to grade each of the following methodological 
domains at “low” “high” or “unclear” risk of bias: sequence generation and allocation 
sequence concealment (selection bias), masking of participants and outcome assessors 
(information bias), trial funding, and author financial relationships.
23
 We resolved 
discrepancies in data abstraction through discussion or consultation with a third person. 
3.2.4 Qualitative synthesis 
We examined clinical, methodological, and statistical heterogeneity. We 
investigated clinical heterogeneity in terms of participant characteristics (e.g. age of 
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participants and baseline IOP) and trial interventions. For methodological heterogeneity, 
we considered study design and risk of bias.  
3.2.5 Quantitative synthesis 
Our analysis did not distinguish between drug concentrations; comparisons were 
based on the active ingredient and class of that ingredient. We first conducted pair-wise 
meta-analyses for all direct comparisons using random-effects models assuming 
comparison-specific heterogeneity and a common heterogeneity across all comparisons at 
both the drug and class level. To assess the statistical heterogeneity, we examined the I
2
 
and tau
2
 values for these models. Pair-wise meta-analyses were conducted in STATA 
13
®
.
24
 
Next, we fit Bayesian random-effects network meta-analysis models based on the 
Lu and Ades approach in WinBUGS 1.4.3.
 25-27
 This model also accounts for the within-
study correlation of multi-arm trials.
25-26
 We applied non-informative, yet proper, priors 
so that the data dominate the posterior distribution. We drew samples of the parameters 
of interest from the full posterior distribution using Markov Chain Monte Carlo (MCMC) 
algorithms. We used 2 chains and obtained 50,000 samples (after a 20,000 sample burn-
in period). Our approach to model class effect was based on the approach used by Mayo-
Wilson et al.
28
 In this model, class effect is estimated from the pooled distribution of 
estimates from individual treatments in that class. This method allows us to use data from 
all trials for class effect, rather than discarding trials comparing drugs from the same 
class. We assumed that variance was homogeneous at both the drug and the class level. 
3.2.6 Evaluation of network meta-analysis assumptions 
A valid network meta-analysis requires the assumption that there are no 
systematic differences between included comparisons other than the treatments 
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themselves.
5
 We examined this assumption based on the distribution of participant 
characteristics, interventions, and design characteristics among trials. We further 
considered the statistical disagreement between direct and indirect comparisons, or 
inconsistency, present among studies. To assess inconsistency, we used the loop-specific 
approach with inconsistency models. For the loop-specific approach, each independent 
closed triangular or quadratic loop (set of three or four treatments connected by direct 
comparisons) in the network is evaluated for inconsistency and incorporated as separate 
parameters (i.e. inconsistency factors) in the model.
29-30
 This analysis was conducted in 
STATA 13
®
.
30-32
 When inconsistency was found, we qualitatively investigated trial 
characteristics such as funding source to determine potential sources of inconsistency. 
3.2.7 Measures of relative treatment effect 
We examined mean differences in IOP (and 95% confidence intervals or credible 
intervals) between drug pairs and drug class pairs. We combined both change from 
baseline values with values at a time point. Due to randomization, it is reasonable to 
assume that both specific metrics are estimating the same effect.
33
 We also determined 
the probability of rank for each drug or class (i.e. the probability of a drug being the most 
efficacious treatment, the second most, etc.). We examined the hierarchy of treatment 
rankings by using the surface below the cumulative ranking curve (SUCRA).
30,34
 A 
SUCRA value (or percentage) gives the probability that a treatment is among the best 
treatments, with a value of 1 (or 100%) meaning that a treatment is certain to be the best 
and 0 (or 0%) meaning that a treatment is certain to be the worst. Rankings based on 
SUCRA values are considered to better take into account uncertainty in estimated 
treatment effects than general ranking probabilities.
30,34 
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3.3 Guideline and network meta-analysis comparison 
 We compared information extracted from each guideline group to the results of 
the corresponding network meta-analysis to assess frequency of matching of 
recommended drugs or drug classes and efficacy estimates in the guideline with the most 
efficacious drug or drug class from the network meta-analysis (based on SUCRA values).  
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4 Results 
4.1 Guideline identification and extraction 
 We identified 9 version of the AAO’s POAG PPP: 1989, 1990, 1992, 1996, 2000, 
2003, 2005, 2006, and 2010.
7,10-17
 Based on recommendations and level of discussion of 
POAG medical therapies, we grouped the guidelines together into 5 different sets: 1991-
1992, 1996, 2000-2003, 2005-2006, and 2010 (Table 1). Of these guideline sets, only 
2010 made recommendations on first-line medical therapy. Based on a meta-analysis of 
11 glaucoma trials, the 2010 guideline stated that “Prostaglandin analogs are the most 
effective drugs at lowering IOP and can be considered as initial medical therapy.” 
However, no other guideline set made any specific recommendations with regard to 
which drug or class of drug is most efficacious; guideline statements have focused on 
describing available options, therapies most often used as first-line treatment, or general 
guidance for treatment. For example, the 2005-2006 guideline set stated that “In many 
instances, topical medications constitute effective initial therapy" instead of making a 
specific recommendation. Of the guideline sets, the 2005-2006 and 2010 sets reported 
stopping points for literature searches. Therefore, the time points for network meta-
analysis were 1991, 1995, 2002, 2004, and 2009, with an additional one comprising all 
collected data up to 2014.  
4.2 Network meta-analysis 
4.2.1 Search results and general study characteristics 
 We identified 10,936 unique records from the search. For this analysis, a total of 
105 RCTs from the published literature met our eligibility criteria (Figure 1; references 
for these trials are available in Appendix II). The first trial was published in 1983 and the 
latest trial in 2013. The network included 18 trials (1,161 participants) by 1991, 29 trials 
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(2,641 participants) by 1995, 66 trials (9,446 participants) by 2002, 76 trials (10,717 
participants) by 2004, and 91 trials (13,870 participants) by 2009. As of 2014, there are a 
total 16,898 participants in the network of 105 trials. Detailed characteristics of 
individual trials are included in Appendix III. 
 The study characteristics described include all trials published by the network 
meta-analysis time point. Sample size of studies appears to be smaller in earlier years 
than later ones. In 1991, the median size of trials was 69 participants (interquartile range 
(IQR): 28 to 85). This increased to 72 participants (IQR: 42 to 137) by 1995, and 95 
participants (IQR: 45 to 177) by 2002. Afterwards, study sample size does not appear to 
change substantially, with a median of 91 participants (IQR: 43 to 195) by 2004 and 90 
participants (IQR: 47 to 213) by 2009. As of 2014, the median sample size of trials is 97 
(IQR: 49 to 218). The smallest trial (17 participants) was published in 1985 and the 
largest (976 participants) in 2005. 
 The proportion of trials reported to be multicenter also appears to be smaller in 
earlier years: 39% of trials were reported to be multicenter in 1991, 55% in 1995, 70% in 
2002, 64% in 2004, 61% in 2009, and 65% as of 2014. Reported regions of participant 
recruitment (in 1991 and 2014 respectively) are North America (28% to 37%), Latin 
America (0% to 3%), Europe (0%  to 17%), Africa (0% to 1%), Asia (6% to 16%), 
Oceania (0% to 2%) (trials could recruit participants from more than one region; 
remaining trials did not report region).  
The length of trials is generally longer for earlier studies. Median trial length was 
6 months (IQR: 3 to 15) in 1991 and 6 months (IQR: 3 to 12) in 1995. For all network 
meta-analysis time points after 1995, median length was 3 months (IQR: 3 to 12). 
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4.2.2 Risk of bias 
 At all network meta-analysis time points, the risk of bias of included studies was 
generally unclear to high, although the proportion of trials with low risk of bias appears 
to be higher at later time points (Figure 2a-f; Appendix IV). The proportion of studies 
with low risk of bias from sequence generation ranges from 11% in 1991 (89% unclear) 
to 43% in 2014 (57% unclear). 17% of studies published by 1991 were rated to have a 
low risk of bias for allocation concealment (83% unclear) while 27% published by 2014 
were (73% unclear). We rated the risk of bias from masking of participants to be low for 
33% of studies up to 1991 (11 % high; 56% unclear) and 39% of studies up to 2014 (21% 
high; 40% unclear). 17% of studies to 1991 (83% unclear) were rated to have a low risk 
of bias due to masking of IOP assessor, and 22% of studies were rated low up to 2014 
(10% high; 69% unclear). In trials published up to 1991, only 33% reported funding, of 
which 100% had industry funding and 33% were funded by government (a trial could 
report more than one funding source). By 2014, 59% reported funding, of which 92% 
reported industry funding and 13% reported government funding. Of trials published by 
1991, 33% reported on author financial conflicts of interest, of which 100% reported 
conflicts of interest for at least one author. By 2014, 52% of trials reported on conflicts of 
interests, of which 67% reported existing conflict of interest for least one author. 
4.2.3 Interventions 
 Included trials studied 13 active interventions from 4 different classes, as well as 
placebo/vehicle/no treatment (Figure 3a-f). The active interventions were apraclonidine 
and brimonidine (alpha-2 adrenergic agonists); betaxolol, carteolol, levobunolol, and 
timolol (beta blockers); brinzolamide and dorzolamide (carbonic anhydrase inhibitors); 
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and bimatoprost, latanoprost, travoprost, tafluprost, and unoprostone (prostaglandin 
analogs). By 1991, three active drugs (betaxolol, levobunolol, and timolol) from one class 
(beta blockers) and placebo were studied in RCTs. In 1995, the network of studies 
included an additional five drugs (apraclonidine, carteolol, dorzolamide, latanoprost, and 
unoprostone), and at least one drug from each class was included. The network expanded 
to 11 active drugs in 2002 with brimonidine, brinzolamide, and travoprost. By 2004, 12 
of the active drugs were in the network and no additional drugs were added in 2009. As 
of 2014, one more drug, tafluprost, has been studied in the network. 
4.2.4 Network meta-analysis outcomes 
 Network meta-analysis indicates that all drugs (and classes) are superior to 
placebo in lowering 3-month IOP at all network meta-analysis time points (Table 2a-l; 
Figure 4a-b). Results are reported in terms of mean IOP (in mmHg) and 95% credible 
interval. The drugs and classes with the largest effect on IOP reduction compared with 
placebo at each time point are: 1991: levobunolol 4.53 (3.31 to 5.79), beta blockers 4.01 
(0.48 to 7.43); 1995: apraclonidine 5.63 (2.56 to 8.64), alpha agonists 5.64 (1.73 to 9.50); 
2002: travoprost 6.02 (4.64 to 7.38), prostaglandins 4.97 (3.29 to 6.65); 2004: 
bimatoprost 5.87 (4.67 to 7.06), prostaglandins 4.75 (3.11 to 6.44); 2009 bimatoprost 
5.87 (4.96 to 6.77), prostaglandins 4.58 (2.94 to 6.24); 2014: bimatoprost 5.55 (4.80 to 
6.31), prostaglandins 4.38 (3.03 to 5.75). Point estimates for drug and class effects appear 
to diminish over time (Figure 4a-b). 
 Many direct comparisons between drugs, such as latanoprost vs placebo, are 
missing even by 2014 and for the direct comparisons that exist, there are often only one 
or two trials (Appendix V). The class effect estimates from direct comparison differ 
greatly from those obtained from combining direct and indirect comparisons. For 
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example, by 2014 only two trials have directly compared prostaglandins with placebo and 
the pooled estimate is not significantly superior to placebo. 
 Ranking probabilities are consistent with the network meta-analysis effect 
estimates (Figure 5a-l). By 2014, for example, bimatoprost had a 93.4% chance of being 
the most efficacious drug in terms of effect on 3-month IOP, 6.1% chance of being the 
second best, and 0.5% chance of being the third best, while as a class, prostaglandins had 
73.9% chance of being the best, 19.8% of being the second best, and 5.4% of being the 
third best. Ranking based on cumulative ranking probabilities from SUCRA plots are also 
generally consistent with effect estimates (Figure 6a-b). The only time at which the 
highest cumulative rank did not match with treatment effect was in 1995, in which 
apraclonidine was had the highest mean effect but levobunolol had the highest 
cumulative ranking. By 2004, rankings generally stabilized for both drugs and classes. 
Sometimes, when two drugs were included at the same time point, they crossed in 
cumulative rank at subsequent points (Figure 6a-b). For example, from 2002 to 2009, 
brimonidine was ranked higher than timolol, but by 2014, their positions switched. 
4.2.5 Inconsistency 
 By 2014, the loop-specific approach to inconsistency indicated evidence of 
inconsistency in 5 of 34 triangular loops (15%). We could not find any qualitative 
reasons to explain inconsistency among studies included in the inconsistent loops.  
4.3 Guideline and network meta-analysis comparison 
 A summary of the comparison between guidelines recommendations and network 
meta-analytic findings is given in Table 3. Based on network-meta-analysis, it would 
have been possible to make treatment recommendations for all guideline sets, such as that 
beta blockers were superior to placebo/no treatment based on RCT data available by 
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1991. The only time evidence from network meta-analysis with the guideline 
recommendation is in 2010, as both indicate that the prostaglandin class should be 
considered the first-line treatment in terms of efficacy.  
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5 Discussion 
 AAO’s POAG PPP did not make specific recommendations for first-line 
treatment until 2010. However, based on network meta-analysis, there was sufficient 
evidence to conclude that medical treatments superior to placebo existed by 1991. The 
2010 recommendation is supported by the network meta-analysis results. The ranking of 
classes based on the effect sizes given in the 2010 guidelines are also consistent with our 
findings. Prostaglandins have the largest effect, beta blockers and alpha agonists are next 
and are very close in effect, and carbonic anhydrase inhibitors are the least effective. In 
both the 2010 guideline and the corresponding network meta-analaysis, even though 
prostaglandins are considered the most efficacious class, the magnitude of IOP reduction 
does not really appear to differ substantially between classes. 
 The AAO’s POAG PPPs do not give recommendations at the drug level. This 
may be because the guideline producers did not want to appear to favor a particular drug 
manufacturer, since some glaucoma drugs, such as bimatoprost, are still under patent. 
Our results indicate that drugs within a class generally have similar effects on IOP. The 
most notable exception is unoprostone, which was the least effective drug at all time 
points since 2004 despite the high ranking of all other prostaglandins. With unoprostone, 
there is uncertainty whether it should be classified as a prostaglandin analogue or not.
35-36
 
Despite being derived from prostaglandin F(2α) like the other prostaglandin drugs, 
pharmacological studies have suggested that unoprostone has a distinct mechanism of 
action compared to the other prostaglandins, and therefore it may not be appropriate to 
group it with these other drugs.
35-36
 If unoprostone is really part of a separate drug class, 
it would explain the great disparity in IOP effect, as well as indicate that our findings for 
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prostaglandin effect may underestimate the true class effect. Other exceptions are 
betaxolol, which has a lower effect than the other beta blockers, and the two alpha 
agonists, apraclonidine and brimonidine, which start off with different effectiveness 
profiles but appear to get closer in effect size and ranking over time. Since within-class 
treatments are generally similar, it is appropriate for guidelines to make recommendations 
at the class level for POAG treatments.  
 One interesting finding from the cumulative network meta-analysis is that, as can 
be seen in Figure 4, there appears to be a consistent pattern that the effect size for all 
glaucoma treatments diminishes over time. Despite this, all treatments are superior to 
placebo at all network meta-analysis time points. This result is consistent with findings 
by Gehr et al., who, in a meta-regression, determined that the effect size for both timolol 
and latanoprost decreased over time.
37
  One potential explanation for this finding is due 
to small-study effects; the tendency for smaller studies to produce larger treatment effects 
than larger studies due to factors like publication bias or poorer methodological quality of 
smaller studies.
38
 Earlier studies in the network were smaller, but even when median 
study size stops increasing in 2002, treatment effect size still diminishes. Another 
possibility is that in earlier studies, participants had less severe disease or more easily 
controlled IOP. After drugs became established in RCTs, people entering trials may be 
those with more severe disease or whose IOP was not controlled on initial therapy. In 
Gehr et al.’s study, it was found that a significant relationship existed between baseline 
IOP values and treatment effect over time in the case of timolol.
37
 We will further explore 
the data to try and determine the decrease in effect size over time. 
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 The AAO PPPs used IOP as the major determinant in forming treatment 
recommendations and so did our analysis, yet it is widely understood that IOP is a 
surrogate outcome for visual function.
39
 Visual field is considered an outcome more 
clinically relevant to visual function, but requires longer follow-up time than IOP to 
accurately assess changes (generally years).
39
 Based on our included studies, median 
follow-up time in POAG trials is 3 months by 2014, preventing meaningful assessment of 
visual field. Some studies, such as the recent UK Glaucoma Treatment Study, which was 
conducted to assess whether latanoprost preserves visual field in addition to reducing 
IOP, have indicated that IOP and visual field are associated.
40
 On the other hand, trials 
such as the Low-Pressure Glaucoma Treatment Study, which found that participants 
assigned to brimonidine had better preserved visual field than those on timolol despite 
mean IOP being similar in both groups, have suggested that depending on IOP is 
questionable.
39,41
 An additional concern is that even if IOP is demonstrated to be a 
reliable predictor for visual field for treatments in one class, different classes may affect 
visual field progression differently despite having a similar ocular hypotensive effect.
39
 In 
terms of the guidelines, the AAO POAG PPPs have considered the evidence associating 
IOP with risk of visual field progression to be sufficient that IOP is an acceptable 
outcome for trials since 1996.
7,13-17
 
 Cumulative pair-wise meta-analysis has demonstrated the importance of using 
meta-analysis instead of just looking at individual RCTs to inform treatment 
recommendations. A cumulative meta-analysis by Antman et al. showed that sufficient 
RCT evidence existed to confirm that thrombolytic therapy significantly reduced the risk 
of death from myocardial infarction by 1973, but that it took 13 years (by which the 
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number of RCTs had increased from 10 to 43) for the therapy to be recommended for 
routine practice by expert reviewers.
42
 
 Network meta-analysis has begun to be recognized as a useful tool for guideline 
developers. The Endocrine Society commissioned a network meta-analysis to be 
conducted to inform recommendations for its 2012 clinical practice guideline for 
osteoporosis in men.
43-44
 The National Institute for Health and Clinical Excellence 
(NICE) in Europe also conducted its own network meta-analysis for making 
recommendations on neuropathic pain treatments.
45
 
By extending the principles of cumulative meta-analysis to network meta-
analysis, we have provided evidence that network meta-analysis can benefit clinical 
guideline developers. If network meta-analysis results had been available to developers, 
the POAG PPP could have made recommendations for initial medical treatment at each 
major update. Furthermore, the current first-line treatment, prostaglandins, could have 
been recommended as early as the 2003 update, seven years earlier than when 
prostaglandins were recommended. Another strength of our analysis is that we were able 
to estimate class effect without discarding trials comparing drugs from the same class. 
Our findings regarding network meta-analysis and guideline comparisons may not 
be applicable to other clinical fields or even other glaucoma guidelines such as those 
developed by the National Institute for Health and Clinical Excellence,
9
 since we only 
examined a single set of guidelines. The cultures of other clinical fields or different 
glaucoma guideline groups may lead them to have different approaches to making 
treatment recommendations (e.g. drug level instead of class level) or in their use of 
evidence as the basis for recommendations. 
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Conclusion 
 We identified 5 sets of guidelines from AAO’s POAG PPPs with major revisions 
in terms of medical treatment recommendations or discussions of therapies. Treatment 
recommendations were only made in the final set. Using cumulative network meta-
analysis, we were able to determine the best drug and class at the time of each major 
revision based on RCT evidence available at the time. Both the final guideline and the 
corresponding network meta-analysis indicate that prostaglandins should be considered 
first-line treatment in terms of IOP reduction. Other findings from the network meta-
analysis are that the effect size for all drugs and classes appears to decrease over time, but 
all were significantly better than placebo at all time points. Network meta-analysis results 
have the potential to help clinical guideline developers make evidence-based 
recommendations. 
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7 Tables 
7.1 Table 1 Recommendations from AAO POAG PPPs 
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7.2 Table 2 Summary estimates for intraocular pressure (mmHg) at 3 months derived from network meta-analysis 
7.2.1 Table 2a Network meta-analysis IOP estimates for drugs from studies published by 1991 
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7.2.2 Table 2b Network meta-analysis IOP estimates for drugs from studies published by 1995 
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7.2.3 Table 2c Network meta-analysis IOP estimates for drugs from studies published by 2002 
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7.2.4 Table 2d Network meta-analysis IOP estimates for drugs from studies published by 2004 
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7.2.5 Table 2e Network meta-analysis IOP estimates for drugs from studies published by 2009 
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7.2.6 Table 2f Network meta-analysis IOP estimates for drugs from studies published by 2014 
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7.2.7 Table 2g Network meta-analysis IOP estimates for classes from studies published by 1991 
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7.2.8 Table 2h Network meta-analysis IOP estimates for classes from studies published by 1995 
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7.2.9 Table 2i Network meta-analysis IOP estimates for classes from studies published by 2002 
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7.2.10 Table 2j Network meta-analysis IOP estimates for classes from studies published by 2004 
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7.2.11 Table 2k Network meta-analysis IOP estimates for classes from studies published by 2009 
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7.2.11 Table 2l Network meta-analysis IOP estimates for classes from studies published by 2014 
 
Color coding: drug class 
Mean difference < 0 favors the drug in the column 
Mean difference > 0 favors the drug in the row 
Reported numbers are calculated by column - row under the Lu and Ades homogeneous random effects model assuming consistency 
Reported posterior means and 95% Bayesian credible intervals 
 
Grey Placebo/vehicle/no treatment 
Orange Alpha-2 adrenergic agonist 
Green Beta-blocker 
Red Carbonic anhydrase inhibitor 
Blue Prostaglandin analog 
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7.3 Table 3. Guideline and network meta-analysis comparison 
 
 
40 
   
8 Figures 
8.1 Figure 1 Selection of studies 
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8.2 Figure 2 Risk of bias figure 
8.2.1 Figure 2a Risk of bias figure for studies published up to 1991 
 
 
 
 
8.2.2 Figure 2b Risk of bias figure for studies published up to 1995 
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8.2.3 Figure 2c Risk of bias figure for studies published up to 2002 
 
 
8.2.4 Figure 2d Risk of bias figure for studies published up to 2004 
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8.2.5 Figure 2e Risk of bias figure for studies published up to 2009 
 
 
 
8.2.6 Figure 2f Risk of bias figure for studies published up to 2014 
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8.3 Figure 3 Network graphs 
8.3.1 Figure 3a Network graph for studies published up to 1991 
 
 
 
8.3.2 Figure 3b Network graph for studies published up to 1995 
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8.3.3 Figure 3c Network graph for studies published up to 2002 
 
 
 
8.3.4 Figure 3d Network graph for studies published up to 2004 
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8.3.5 Figure 3e Network graph for studies published up to 2009 
 
 
 
8.3.6 Figure 3f Network graph for studies published up to 2014 
 
Each node represents one drug. The drugs are color-coded by class. The size of the node is proportional to 
the number of participants randomized to that drug. 
 
The edges represent direct comparisons (i.e. when there is a line connecting two drugs, the two drugs have 
been compared directly to each other in a trial). The width of the edge is proportional to the number of 
trials. 
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8.4 Figure 4 Funnel plots of treatment effect relative to placebo at each 
network meta-analysis time point 
8.4.1 Figure 4a Funnel plot for drug effect relative to placebo 
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8.4.2 Figure 4b Funnel plot for class effect relative to placebo 
 
 
Since glaucoma drugs are expected to lower IOP values, more negative IOP values indicate greater effect.
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8.5 Figure 5 Ranking probabilities for any treatment at any position 
8.5.1 Figure 5a Ranking probabilities for any drug at any position from studies published by 1991 
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8.5.2 Figure 5b Ranking probabilities for any drug at any position from studies published by 1995 
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8.5.3 Figure 5c Ranking probabilities for any drug at any position from studies published by 2002 
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8.5.4 Figure 5d Ranking probabilities for any drug at any position from studies published by 2004 
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8.5.5 Figure 5e Ranking probabilities for any drug at any position from studies published by 2009 
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8.5.6 Figure 5f Ranking probabilities for any drug at any position from studies published by 2014 
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8.5.7 Figure 5g Ranking probabilities for any class at any position from studies published by 1991 
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8.5.8 Figure 5h Ranking probabilities for any class at any position from studies published by 1995 
 
  
0.000 
0.099 0.066 
0.318 
0.517 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Rank 5
Rank 4
Rank 3
Rank 2
Rank 1
 
57 
 
8.5.9 Figure 5i Ranking probabilities for any class at any position from studies published by 2002 
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8.5.10 Figure 5j Ranking probabilities for any class at any position from studies published by 2004 
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8.5.11 Figure 5k Ranking probabilities for any class at any position from studies published by 2009 
 
  
 
60 
 
8.5.12 Figure 5l Ranking probabilities for any class at any position from studies published by 2014 
 
Warmer colors indicate better ranks 
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8.6 Figure 6 Cumulative ranking of treatments at each network meta-
analysis time point 
8.6.1 Figure 6a Cumulative ranking of drugs at each network meta-analysis 
time point 
 
 
8.6.2 Figure 6b Cumulative ranking of class at each network meta-analysis 
time point
 
SUCRA percentage is the probability a treatment has of being among the best treatments (e.g. 
100% if certainly the best, 0% if certainly the worst)  
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Appendix I. Search Strategy 
Cochrane Library 
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees 
#2 MeSH descriptor: [Ocular Hypertension] explode all trees 
#3 (open near/2 angle near/2 glaucoma*)  
#4 (POAG or OHT)  
#5 (((increas* or elevat* or high*) near/3 (ocular or intra-ocular)) and 
pressure)  
#6 {or #1-#5}  
#7 MeSH descriptor: [Adrenergic beta-Antagonists] explode all trees 
#8 MeSH descriptor: [Timolol] explode all trees 
#9 Timolol*  
#10 MeSH descriptor: [Metipranolol] explode all trees 
#11 Metipranolol*  
#12 MeSH descriptor: [Carteolol] explode all trees 
#13 Carteolol*  
#14 MeSH descriptor: [Levobunolol] explode all trees 
#15 Levobunolol*  
#16 MeSH descriptor: [Betaxolol] explode all trees 
#17 Betaxolol*  
#18 MeSH descriptor: [Carbonic Anhydrase Inhibitors] explode all trees 
#19 (Carbonic near/2 Anhydrase near/2 Inhibitor*)  
#20 MeSH descriptor: [Acetazolamide] explode all trees 
#21 Acetazolam*  
#22 Brinzolamide*  
#23 Dorzolamide*  
#24 MeSH descriptor: [Prostaglandins, Synthetic] explode all trees 
#25 latanoprost*  
#26 travoprost*  
#27 bimatoprost*  
#28 unoprostone*  
#29 tafluprost*  
#30 MeSH descriptor: [Antihypertensive Agents] explode all trees 
#31 MeSH descriptor: [Pilocarpine] explode all trees 
#32 Pilocarpin*  
#33 MeSH descriptor: [Epinephrine] explode all trees 
#34 epinephrine*  
#35 dipivefrin*  
#36 MeSH descriptor: [Adrenergic alpha-2 Receptor Agonists] explode all 
trees 
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#37 (adrenergic near/2 alpha* near/3 agonist*)  
#38 apraclonidin*  
#39 brimonidine*  
#40 (drug* or medic* or pharmacologic*) near/3 (treat* or therap* or 
intervent*)  
#41 {or #7-#40}  
#42 #6 and #41 
  
  
MEDLINE  (OVID) 
1. exp clinical trial/ [publication type]   
2. (randomized or randomised).ab,ti.   
3. placebo.ab,ti.   
4. dt.fs.   
5. randomly.ab,ti.   
6. trial.ab,ti.   
7. groups.ab,ti.   
8. or/1-7   
9. exp animals/   
10. exp humans/   
11. 9 not (9 and 10)   
12. 8 not 11   
13. exp glaucoma open angle/   
14. exp ocular hypertension/   
15. (open adj2 angle adj2 glaucoma$).tw.   
16. (POAG or OHT).tw.   
17. (((increas$ or elevat$ or high$) adj3 (ocular or intra-ocular)) and pressure).tw. 
  
18. or/13-17   
19. exp adrenergic beta antagonists/   
20. exp timolol/   
21. timolol$.tw.   
22. exp metipranolol/   
23. metipranolol$.tw.   
24. exp carteolol/   
25. carteolol$.tw.   
26. exp levobunolol/   
27. levobunolol$.tw.   
28. exp betaxolol/   
29. betaxolol$.tw.   
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30. exp carbonic anhydrase inhibitors/   
31. (carbonic adj2 anhydrase adj2 inhibitor$).tw.   
32. exp Acetazolamide/   
33. acetazolamide$.tw.   
34. brinzolamide$.tw.   
35. dorzolamide$.tw.   
36. exp Prostaglandins, Synthetic/   
37. latanoprost$.tw.   
38. travoprost$.tw.   
39. bimatoprost$.tw.   
40. unoprostone$.tw.   
41. brimonidine$.tw.   
42. exp antihypertensive agents/   
43. exp pilocarpine/   
44. pilocarpin$.tw.   
45. exp epinephrine/   
46. epinephrin$.tw.   
47. dipivefrin$.tw.   
48. exp Adrenergic alpha-2 Receptor Agonists/   
49. ((adrenergic adj2 alpha$ adj2 receptor$) or (adrenergic adj2 alpha$ adj2 
agonist$)).tw.   
50. apraclonidin$.tw.   
51. tafluprost$.tw.   
52. ((drug$ or medic$ or pharmacologic$) adj3 (treat$ or therap$ or 
intervent$)).tw.   
53. or/19-52   
54. 18 and 53   
55. 12 and 54  
  
Embase.com 
#1 'randomized controlled trial'/exp 
#2 'randomization'/exp 
#3 'double blind procedure'/exp 
#4 'single blind procedure'/exp 
#5 random*:ab,ti 
#6 #1 OR #2 OR #3 OR #4 OR #5 
#7 'animal'/exp OR 'animal experiment'/exp 
#8 'human'/exp 
#9 #7 AND #8 
#10 #7 NOT #9 
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#11 #6 NOT #10 
#12 'clinical trial'/exp 
#13 (clin* NEAR/3 trial*):ab,ti 
#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR 
mask*)):ab,ti 
#15 'placebo'/exp 
#16 placebo*:ab,ti 
#17 random*:ab,ti 
#18 'experimental design'/exp 
#19 'crossover procedure'/exp 
#20 'control group'/exp 
#21 'latin square design'/exp 
#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 
OR #21 
#23 #22 NOT #10 
#24 #23 NOT #11 
#25 'comparative study'/exp 
#26 'evaluation'/exp 
#27 'prospective study'/exp 
#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti 
#29 #25 OR #26 OR #27 OR #28 
#30 #29 NOT #10 
#31 #30 NOT (#11 OR #23) 
#32 #11 OR #24 OR #31 
#33 'open angle glaucoma'/exp 
#34 'intraocular hypertension'/exp 
#35 (open NEAR/2 angle):ab,ti AND (angle NEAR/2 glaucoma*):ab,ti 
#36 poag:ab,ti OR oht:ab,ti 
#37 ((increas* OR elevat* OR high*) NEAR/3 (ocular OR 'intra ocular')):ab,ti 
AND pressure:ab,ti 
#38 #33 OR #34 OR #35 OR #36 OR #37 
#39 'beta adrenergic receptor blocking agent'/exp 
#40 'timolol'/exp 
#41 timolol*:ab,ti 
#42 'metipranolol'/exp 
#43 metipranolol*:ab,ti 
#44 'carteolol'/exp 
#45 carteolol*:ab,ti 
#46 'levobunolol'/exp 
#47 levobunolol*:ab,ti 
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#48 'betaxolol'/exp 
#49 betaxolol*:ab,ti 
#50 'carbonate dehydratase inhibitor'/exp 
#51 (carbonic NEAR/2 anhydrase):ab,ti AND (anhydrase NEAR/2 
inhibitor*):ab,ti 
#52 'acetazolamide'/exp 
#53 acetazolamide*:ab,ti 
#54 brinzolamide*:ab,ti 
#55 dorzolamide*:ab,ti 
#56 'latanoprost'/exp 
#57 latanoprost*:ab,ti 
#58 'travoprost'/exp 
#59 travoprost*:ab,ti 
#60 'bimatoprost'/exp 
#61 bimatoprost*:ab,ti 
#62 'unoprostone isopropyl ester'/exp 
#63 unoprostone*:ab,ti 
#64 'brimonidine'/exp 
#65 brimonidine*:ab,ti 
#66 'antihypertensive agent'/exp 
#67 'pilocarpine'/exp 
#68 pilocarpin*:ab,ti 
#69 'adrenalin'/exp 
#70 epinephrin*:ab,ti 
#71 dipivefrin*:ab,ti 
#72 'alpha 2 adrenergic receptor stimulating agent'/exp 
#73 (adrenergic NEAR/2 alpha*):ab,ti AND (alpha* NEAR/2 agonist*):ab,ti 
#74 apraclonidin*:ab,ti 
#75 'tafluprost'/exp 
#76 tafluprost*:ab,ti 
#77 ((drug* OR medic* OR pharmacologic*) NEAR/3 (treat* OR therap* OR 
intervent*)):ab,ti 
#78 #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 
OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 OR #55 OR #56 OR 
#57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 
OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR 
#76 OR #77 
#79 #38 AND #78 
#80 #32 AND #79 
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PubMed  
#1 ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR 
(randomised[tiab] OR randomized[tiab]) OR (placebo[tiab]) OR (drug 
therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT 
(animals[mh] NOT humans[mh]) 
#2  (open[tw] AND angle[tw] AND glaucoma*[tw]) NOT Medline[sb]  
#3 (POAG[tw] OR OHT[tw]) NOT Medline[sb]  
#4 (((increase*[tw] OR elevat*[tw] OR high*[tw]) AND (ocular[tw] OR 
intra-ocular[tw])) AND pressure[tw]) NOT Medline[sb]  
#5 #2 OR #3 OR #4 
#6  timolol*[tw] NOT Medline[sb]  
#7 metipranolol*[tw] NOT Medline[sb]  
#8 carteolol*[tw] NOT Medline[sb]  
#9 levobunolol*[tw] NOT Medline[sb]  
#10 betaxolol*[tw] NOT Medline[sb]  
#11 (carbonic[tw] AND anhydrase[tw] AND inhibitor*[tw]) NOT Medline[sb]  
#12 acetazolamide*[tw] NOT Medline[sb]  
#13 brinzolamide*[tw] NOT Medline[sb]  
#14 dorzolamide*[tw] NOT Medline[sb]  
#15 latanoprost*[tw] NOT Medline[sb]  
#16 travoprost*[tw] NOT Medline[sb]  
#17 bimatoprost*[tw] NOT Medline[sb]  
#18 unoprostone*[tw] NOT Medline[sb]  
#19 brimonidine*[tw] NOT Medline[sb]  
#20 pilocarpin*[tw] NOT Medline[sb]  
#21 epinephrin*[tw] NOT Medline[sb]  
#22 dipivefrin* NOT Medline[sb]  
#23 ((adrenergic[tw] AND alpha*[tw] AND receptor*[tw]) OR 
(adrenergic[tw] AND alpha*[tw] AND agonist*[tw])) NOT Medline[sb]  
#24 apraclonidin*[tw] NOT Medline[sb]  
#25 tafluprost*[tw] NOT Medline[sb]  
#26 ((drug*[tw] OR medic*[tw] OR pharmacologic*[tw]) AND (treat*[tw] 
OR therap*[tw] OR intervent*[tw])) NOT Medline[sb]  
#27 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR 
#15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 
OR #25 OR #26 
#28  #5 AND #27 
#29 #1 AND #2 
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Appendix III. Characteristics of included studies 
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Appendix IV. Risk of bias table 
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Appendix V. Pair-wise meta-analysis 
App V. Table 1. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
1991 
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App V. Table 3. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
2002 
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App V. Table 2. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
1995 
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App V. Table 4. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
2004 
 
  
 
96 
 
App V. Table 5. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
2009 
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App V. Table 6. Summary estimates for intraocular pressure at 3 months 
derived from pair-wise meta-analysis for drugs in studies published by 
2014 
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App V. Table 7. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 1991 
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App V. Table 8. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 1995 
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App V. Table 8. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 2002 
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App V. Table 9. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 2004 
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App V. Table 10. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 2009 
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App V. Table 11. Summary estimates for intraocular pressure at 3 months derived from pair-wise meta-analysis for 
classes in studies published by 2014 
 
a 
Mean difference is calculated using the intraocular pressure of the treatment in column 2 - column 1 
Mean difference > 0 favors the drug in column 1 
Mean difference <  0 favors the drug in column 2 
Color coding: 
Grey Placebo/vehicle/no treatment 
Orange Alpha-2 adrenergic agonist 
Green Beta-blocker 
Red Carbonic anhydrase inhibitor 
Blue Prostaglandin analog 
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